Ayvakyt® – sustained symptom reduction in inadequately controlled ISM

Avapritinib (Ayvakyt)^®) from Blueprint Medicines is the first therapy that targets the cause of the disease to treat indolent systemic mastocytosis (ISM) – and the first that can achieve lasting symptom reduction despite optimal supportive therapy in cases of moderate or severe symptoms.